Efficacy and Safety of IL ‐17 and IL ‐23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real‐World Study
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17755 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Fatmanur Hacınecipoğlu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ankara Etlik City Hospital, Ankara, Türkiye. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Interleukin-23, Dermatologic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Biologic therapies targeting interleukin (IL)‐17 and IL‐23 have transformed psoriasis treatment, yet real‐world evidence on the impact of age on treatment responses and drug survival is limited. This study aims to compare early (12/16 weeks), mid term (24 weeks) and long term (52 weeks) Psoriasis Area and Severity Index (PASI) responses and drug survival in psoriasis patients aged < 65 versus ≥ 65 years receiving IL‐17 or IL‐23 inhibitors. In this retrospective study, 121 patients with moderate‐to‐severe plaque psoriasis treated with secukinumab, ixekizumab, guselkumab, or risankizumab were analyzed. Patients were stratified into two age groups (< 65, n = 78; ≥ 65, n = 43). PASI75, PASI90, and PASI < 2 outcomes were assessed at 12/16, 24, and 52 weeks. Drug survival was evaluated via Kaplan–Meier analysis (censoring at 24 months) and Cox regression was used to identify predictors of discontinuation. At 12/16 weeks, the < 65 group achieved significantly higher PASI75 (90.5% vs. 65.1%, p = 0.010), PASI90 (75.7% vs. 32.6%, p = 0.030) and PASI < 2 (55.8% vs. 79.7%, p = 0.006) responses than the ≥ 65 group. At 52 weeks, PASI75, PASI90, and PASI < 2 rates were similar between groups (86.3% vs. 97.5%, p = 0.055; 78% vs. 90%, p = 0.112; 85.1% vs. 92.5%, p = 0.253). There were no significant differences between IL‐17 and IL‐23 inhibitors within any age group. Overall drug survival at 24 months was high (79.6% for < 65 and 90.3% for ≥ 65, log‐rank p = 0.407), with no difference between biologic classes (mean survival: 21.8 vs. 22.4 months, p = 0.520). In Cox regression, female sex (HR 0.23, p = 0.005) and higher baseline PASI (HR 1.093 per point, p = 0.013) predicted discontinuation, whereas age, biologic class, BMI, and prior biologic use were not significant. Despite a delayed initial response, older patients achieve long‐term PASI outcomes comparable to younger patients when treated with IL‐17 and IL‐23 inhibitors. Drug survival is similarly excellent across age groups and biologic classes. These findings support the successful use of modern biologics in elderly psoriasis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Ankara Etlik City Hospital, Ankara, Türkiye.
ORCID-Profile: Fatmanur Hacınecipoğlu, Gökçen Çelik, Selda Pelin Kartal
Zitieren
APA
Hacınecipoğlu, F., Çelik, G., & Kartal, S. P. (2025). Efficacy and Safety of IL ‐17 and IL ‐23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real‐World Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17755
Vancouver
Hacınecipoğlu F, Çelik G, Kartal SP. Efficacy and Safety of IL ‐17 and IL ‐23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real‐World Study. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17755
BibTeX
@article{Hacnecipolu2025,
author = {Hacınecipoğlu, Fatmanur and Çelik, Gökçen and Kartal, Selda Pelin},
title = {Efficacy and Safety of IL ‐17 and IL ‐23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real‐World Study},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17755}
}
EUVIMED